Berenberg downgrades Eli Lilly stock rating to Hold on plateauing obesity market

Berenberg downgraded Eli Lilly (LLY) from Buy to Hold, lowering its price target to $830 from $970, citing a plateauing in the obesity market upgrade cycle and forecasts that now fall slightly below consensus expectations, despite the company's strong fundamentals and significant past shareholder returns. This re-rating comes amidst several positive recent developments for Eli Lilly, including the launch of an AI drug discovery platform and promising clinical trial results for Jaypirca, pirtobrutinib, and a Breakthrough Therapy designation for olomorasib in oncology, which underscore its ongoing pipeline advancements.

Analysis

Berenberg has downgraded Eli Lilly (LLY) to Hold from Buy, reducing its price target to $830 from $970, based on a perceived 'plateauing in the obesity market upgrade cycle' and forecasts that now sit slightly below consensus. This valuation-driven call contrasts with the company's historical performance, which includes a 413% shareholder return over five years, significantly outpacing the 71% sector average. The downgrade occurs while LLY trades at high earnings multiples, and analyst price targets show a wide dispersion from $650 to $1,190, indicating significant debate on its valuation. Concurrently, Eli Lilly has announced several positive fundamental developments that bolster its long-term outlook beyond obesity. These include the launch of Lilly TuneLab, a proprietary AI drug discovery platform; a successful Phase 3 trial for Jaypirca in chronic lymphocytic leukemia (CLL); promising front-line study results for pirtobrutinib, also for CLL; and an FDA Breakthrough Therapy designation for olomorasib in non-small cell lung cancer. These pipeline advancements, particularly in oncology, create a counter-narrative to Berenberg’s more cautious near-term view on the company's primary growth driver.

Key Decisions for Investors

• Investors should weigh the near-term valuation risk, highlighted by Berenberg's downgrade and the stock's high multiples, against the company's long-term growth potential from its robust oncology pipeline and new AI platform.
• It is crucial to monitor consensus earnings revisions for the obesity franchise to determine if Berenberg's thesis of a 'plateauing' upgrade cycle gains broader traction among analysts.
• The recent successful clinical trial results and FDA designation in oncology may signal a strategic de-risking of Eli Lilly's portfolio, which could help sustain its premium valuation if the market begins to price in growth beyond the core diabetes and obesity segments.